Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2012, Article ID 581363, 10 pages
http://dx.doi.org/10.1155/2012/581363
Review Article

Lipoplatin Formulation Review Article

1First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
2Regulon Inc. and Regulon AE, Afxentiou 7, Alimos, 17455 Athens, Greece

Received 29 May 2011; Accepted 24 June 2011

Academic Editor: Rassoul Dinarvand

Copyright © 2012 G. P. Stathopoulos and T. Boulikas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. H. Einhorn, S. D. Williams, P. J. Loehrer et al., “Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol,” Journal of Clinical Oncology, vol. 7, no. 3, pp. 387–391, 1989. View at Google Scholar · View at Scopus
  2. K. Aabo, M. Adams, P. Adnitt et al., “Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials,” British Journal of Cancer, vol. 78, no. 11, pp. 1479–1487, 1998. View at Google Scholar · View at Scopus
  3. J. P. Pignon, J. Bourhis, C. Domenge, and L. Designe, “Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data,” The Lancet, vol. 355, no. 9208, pp. 949–955, 2000. View at Google Scholar · View at Scopus
  4. Non-small Cell Lung Cancer Collaborative Group, “Chemotherapy in non-small cell lung cancer, a meta-analysis using updated data on individual patients from 52 randomized clinical trials,” British Medical Journal, vol. 311, no. 7010, pp. 899–909, 1995. View at Google Scholar
  5. D. Kaufman, D. Raghavan, M. Carducci et al., “Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer,” Journal of Clinical Oncology, vol. 18, no. 9, pp. 1921–1927, 2000. View at Google Scholar · View at Scopus
  6. B. Rosenberg, “Platinum complexes for the treatment of cancer: why the research goes on,” in Cisplatin: Chemistry of a Leading Anticancer Drug, B. Lippert, Ed., pp. 3–12, Verlag Helvetica Chemica Acta, Zurich, Switzerland, 1999. View at Google Scholar
  7. D. M. Hayes, E. Cvitkovic, R. B. Golbey, E. Scheiner, L. Helson, and I. H. Krakoff , “High dose cis-platinum diamminedichloride: amelioration of renal toxicity by mannitol diuresis,” Cancer, vol. 39, pp. 1372–1378, 1977. View at Google Scholar
  8. C. M. Sorenson and A. Eastman, “Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks,” Cancer Research, vol. 48, no. 16, pp. 4484–4488, 1988. View at Google Scholar · View at Scopus
  9. D. R. Gandara, N. A. Nahhas, M. D. Adelson et al., “Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatinum-induced toxicities,” Journal of Clinical Oncology, vol. 13, no. 3, pp. 490–496, 1995. View at Google Scholar
  10. I. Arany and R. L. Safirstein, “Cisplatin nephrotoxicity,” Seminars in Nephrology, vol. 23, no. 5, pp. 460–464, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. E. Taylor, E. Wiltshaw, M. E. Gore, I. Fryatt, and C. Fisher, “Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer,” Journal of Clinical Oncology, vol. 12, no. 10, pp. 2066–2070, 1994. View at Google Scholar · View at Scopus
  12. A. Tognoni, F. Pensa, F. Vaira et al., “A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer,” Journal of Chemotherapy, vol. 14, no. 3, pp. 296–300, 2002. View at Google Scholar
  13. B. E. Johnson, “Integration of new agents into the treatment of advanced non-small cell lung cancer,” in American Society of Clinical Oncology Educational Book, pp. 345–356, Lipincott Williams and Wilkins, Baltimore, Md, USA, 2000. View at Google Scholar
  14. F. A. Shepherd, J. Dancey, A. Arnold et al., “Phase II study of pemetrexed disodium, a multitargeted antifolate and cisplatin as first-line therapy in patients with advanced non-small cell lung cancer,” Cancer, vol. 92, no. 3, pp. 595–600, 2001. View at Google Scholar
  15. F. Barlesi and J. L. Pujal, “Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systemic review of phase III trials,” Lung Cancer, vol. 49, no. 3, pp. 289–298, 2005. View at Google Scholar
  16. G. P. Stathopoulos, M. Veslemes, N. Georgatou et al., “Paclitaxel and vinorelbine combination in advanced inoperable adenocarcinoma of the lung: a phase II study,” Anticancer Research, vol. 23, no. 4, pp. 3479–3484, 2003. View at Google Scholar · View at Scopus
  17. G. P. Stathopoulos, J. Dimitroulis, D. Antoniou et al., “Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial,” British Journal of Cancer, vol. 93, no. 10, pp. 1106–1111, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. A. Ardizzoni, L. Boni, M. Tiseo et al., “Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis,” Journal of the National Cancer Institute, vol. 99, no. 11, pp. 847–857, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. T. Boulikas, G. P. Stathopoulos, N. Volakakis, and M. Vougiouka, “Systemic lipoplatin infusion results in preferential tumor uptake in human studies,” Anticancer Research, vol. 25, no. 4, pp. 3031–3040, 2005. View at Google Scholar · View at Scopus
  20. Boulikas Teni, “Lipoplatin: a successful cisplatin formulation,” Cancer Therapy. In press.
  21. M. T. Kuo, H. H. W. Chen, I. S. Song, N. Savaraj, and T. Ishikawa, “The roles of copper transporters in cisplatin resistance,” Cancer and Metastasis Reviews, vol. 26, no. 1, pp. 71–83, 2007. View at Publisher · View at Google Scholar · View at PubMed
  22. G. Huang, L. Mills, and L. L. Worth, “Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells,” Molecular Cancer Therapeutics, vol. 6, no. 5, pp. 1610–1619, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. Q. Wei, G. Dong, J. Franklin, and Z. Dong, “The pathological role of Bax in cisplatin nephrotoxicity,” Kidney International, vol. 72, no. 1, pp. 53–62, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. J. Zhu, Y. Yang, and J. Wu, “Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis,” Cell Research, vol. 17, no. 5, pp. 441–448, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. T. Boulikas and M. Vougiouka, “Cisplatin and platinum drugs at the molecular level. (Review),” Oncology Reports, vol. 10, no. 6, pp. 1663–1682, 2003. View at Google Scholar
  26. D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 307–320, 2005. View at Publisher · View at Google Scholar · View at PubMed
  27. M. Villedieu, M. Briand, M. Duval, J. F. Heron, P. Gauduchon, and L. Poulain, “Anticancer and chemosensitizing effects of 2,3-DCPE in ovarian carcinoma cell lines: link with ERK activation and modulation of p21(WAF1/CIP1), Bcl-2 and Bcl-x(L) expression,” Gynecologic Oncology, vol. 105, no. 2, pp. 373–384, 2007. View at Google Scholar
  28. M. Singh, H. Sharma, and N. Singh, “Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway,” Mitochondrion, vol. 7, no. 6, pp. 367–373, 2007. View at Publisher · View at Google Scholar · View at PubMed
  29. M. Berndtsson, M. Hägg, T. Panaretakis, A. M. Havelka, M. C. Shoshan, and S. Linder, “Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA,” International Journal of Cancer, vol. 120, no. 1, pp. 175–180, 2007. View at Publisher · View at Google Scholar · View at PubMed
  30. T. Ohta, M. Ohmichi, T. Hayasaka et al., “Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models,” Endocrinology, vol. 147, no. 4, pp. 1761–1769, 2006. View at Publisher · View at Google Scholar · View at PubMed
  31. A. Fedier, R. Erdmann, T. Boulikas, and D. Fink, “Potential of the Akt inhibitor LY294005 to antagonize the efficacy of cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner,” International Journal of Oncology, vol. 29, no. 5, pp. 1303–1310, 2006. View at Google Scholar
  32. J. Bodo, L. Hunakova, P. Kvasnicka et al., “Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations,” British Journal of Cancer, vol. 95, no. 10, pp. 1348–1353, 2006. View at Publisher · View at Google Scholar · View at PubMed
  33. A. Stoeck, D. Gast, M. P. Sanderson, Y. Issa, P. Gutwein, and P. Altevogt, “L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells,” Gynecologic Oncology, vol. 104, no. 2, pp. 461–469, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. C. Arienti, A. Tesei, A. Ravaioli et al., “Activity of lipoplatin in tumor and in normal cells in vitro,” Anticancer Drugs, vol. 19, no. 10, pp. 983–990, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. A. Fedier, C. Poyet, D. Perucchini, T. Boulikas, and D. Fink, “MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal,” Anticancer Drugs, vol. 17, no. 3, pp. 315–323, 2006. View at Publisher · View at Google Scholar
  36. P. Devarajan, R. Tarabishi, J. Mishra et al., “Low renal toxicity of lipoplatin compared to cisplatin in animals,” Anticancer Research, vol. 24, no. 4, pp. 2193–2200, 2004. View at Google Scholar
  37. A. K. Marr, I. D. Kurzman, and D. M. Vail, “Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs,” American Journal of Veterinary Research, vol. 65, no. 11, pp. 1474–1478, 2004. View at Publisher · View at Google Scholar
  38. M. E. Froudarakis, L. Greillier, S. Monjanel-Mouterde et al., “Intrapleural administration of lipoplatin in an animal model,” Lung Cancer, vol. 72, no. 1, pp. 78–83, 2010. View at Publisher · View at Google Scholar · View at PubMed
  39. T. Tippayamontri, R. Kotb, B. Paquette, and L. Sanche, “Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116,” Investigational New Drugs. In press. View at Publisher · View at Google Scholar · View at PubMed
  40. G. Charest, B. Paquette, D. Fortin, D. Mathieu, and L. Sanche, “Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation,” Journal of Neuro-Oncology, vol. 97, no. 2, pp. 187–193, 2010. View at Publisher · View at Google Scholar · View at PubMed
  41. G. P. Stathopoulos, T. Boulikas, M. Vougiouka et al., “Pharmacokinetics and adverse reactions of a new liposomal cisplatin (lipoplatin): phase I study,” Oncology Reports, vol. 13, no. 4, pp. 589–595, 2005. View at Google Scholar
  42. G. P. Stathopoulos, T. Boulikas, M. Vougiouka, S. K. Rigatos, and J. G. Stathopoulos, “Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study,” Oncology Reports, vol. 15, no. 5, pp. 1201–1204, 2006. View at Google Scholar
  43. M. E. Froudarakis, A. Pataka, P. Pappas et al., “Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma,” Cancer, vol. 113, no. 10, pp. 2752–2760, 2008. View at Publisher · View at Google Scholar · View at PubMed
  44. G. P. Stathopoulos, S. K. Rigatos, and J. Stathopoulos, “Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study,” Anticancer Research, vol. 30, no. 4, pp. 1317–1321, 2010. View at Google Scholar
  45. M. I. Koukourakis, A. Giatromanolaki, M. Pitakoudis et al., “Concurrent liposomal cisplatin (lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I-II study,” International Journal of Radiation Oncology Biology Physics, vol. 78, no. 1, pp. 150–155, 2009. View at Publisher · View at Google Scholar · View at PubMed
  46. G. Karpathiou, E. Argiana, A. Koutsopoulos, and M. E. Froudarakis, “Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine,” Oncology, vol. 73, no. 5-6, pp. 426–429, 2008. View at Publisher · View at Google Scholar · View at PubMed
  47. C. F. Jehn, T. Boulikas, A. Kourvetaris, K. Possinger, and D. Luftner, “Pharmacokinetics of liposomal cisplatin (lipoplatin) in combination with 5-FU in patients with advanced head and neck cancer: first results of a phase III study,” Anticancer Research, vol. 27, no. 1, pp. 471–476, 2007. View at Google Scholar
  48. F. S. Farhat, K. Ibrahim, J. Kattan et al., “Preliminary results of phase II study of liposomal cisplatin—vinorelbine combination as first-line treatment in HER2/neu negative metastatic breast cancer (MBC),” in Proceedings of the ASCO Annual Meeting, 2009.
  49. N. Mylonakis, A. Athanasiou, N. Ziras et al., “Phase II study of liposomal cisplatin (lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer,” Lung Cancer, vol. 68, no. 2, pp. 240–247, 2010. View at Publisher · View at Google Scholar · View at PubMed
  50. G. P. Stathopoulos, D. Antoniou, J. Dimitroulis et al., “Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial,” Annals of Oncology, vol. 21, no. 11, pp. 2227–2232, 2010. View at Publisher · View at Google Scholar · View at PubMed
  51. G. P. Stathopoulos, D. Antoniou, J. Dimitroulis, J. Stathopoulos, K. Marosis, and P. Michalopoulou, “Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small cell lung cancer,” Cancer Chemotherapy and Pharmacology. In press. View at Publisher · View at Google Scholar · View at PubMed